JPRN-C000000414
Completed
未知
Clinical study of adjuvant immuno-cell therapy for pancreatic cancer curatively resectable. - Clinical study of adjuvant immuno-cell therapy for pancreatic cancer curatively resectable.
ConditionsPancreatic cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Pancreatic cancer
- Sponsor
- Yokohama City University Hospital
- Enrollment
- 10
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who have: uncontrolled infections, active autoimmune diseases, and serious cardiac disease; who have received continuous systemic steroids; who are pregnant, to be pregnant, or nursing mothers, and whom principle investigator or co\-investigator judged to be inappropriate to participate in this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
A phase I clinical study of immune cell therapy with MAGE-A4- or Survivin-specific Th1 cells for patients with refractory virulent tumorsRefractory cancer patients (MAGE-A4- or Survivin-expressing, non origin-limited) or the patients who refuse standard cancer therapyJPRN-UMIN000004828Department of General Surgery, Hokkaido University Graduated School of Medicine18
Not yet recruiting
Phase 1
Gastric cancer immunotherapyIRCT20170208032451N1Mashhad University of Medical Sciences5
Completed
Not Applicable
Phase I study of immuno-Cell therapy for advanced and recurrent esophageal squamous cell carcinomaAdvanced and recurrent esophageal squamous cell carcinomaJPRN-UMIN000007841Toho University5
Active, not recruiting
Phase 2
A CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF PT 107 (VACCINE) IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTSHealth Condition 1: null- Advanced non-small cell lung cancer (Stages IIIB/IV) who have failed first line of chemotherapyCTRI/2010/091/001348PIQUE THERAPEUTICS INC100
Active, not recruiting
Phase 1
Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable, high-risk, localized urothelial carcinoma of the upper urinary tract.The patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter. Presence of divergent histologies (i.e. squamous-cell tumor, adenocarcinoma, small cell carcinoma, micropapillary variant) may be acceptable provided that there is an important prevalence (> 90%) of urothelial component.MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-001028-32-FRCHU DE NIMES99